Skip to main content
. 2019 Mar 20;5(3):eaav5010. doi: 10.1126/sciadv.aav5010

Fig. 5. DCL-Dox inhibits TNBC lung metastasis and improves survival.

Fig. 5

(A) Schematic design of TNBC lung metastasis therapy. (B) Representative bioluminescence images of lung metastasis at different time points in mice treated with the following agents: PBS (sham), free Dox, IgG-Dox-LP, ICAM-Dox-LP, EGFR-Dox-LP, or DCL-Dox_4.2/1 (n = 8 per group). (C) Representative tumor progression curves as depicted from in vivo bioluminescence signal intensity (n = 3 per group). (D) Size and morphology of lungs excised from mice in different treatment groups. (E) Quantification of metastasis node numbers on excised lungs from mice in different treatment groups. (F) Metastasis-free survival of mice in DCL-Dox and control groups as displayed by Kaplan-Meier curves (log-rank test). (G) Schematic design for dosage-dependent therapy. iv, intravenous. (H) In vivo bioluminescence images of mice in the dosage-dependent study. Tumor-bearing mice were treated with DCL-Dox_4.2/1 at different dosages and imaged at day 74 or an earlier sacrifice date (n = 5 per group). “*” indicates the mouse sacrificed at day 22 due to blindness caused by retro-orbital injection). (I) Quantification of metastasis node numbers on excised lungs in the dosage-dependent study. (J) Metastasis-free survival of mice in the dosage-dependent study as displayed by Kaplan-Meier curves (log-rank test). (K) Serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, and blood urea nitrogen (BUN) (n = 4 to 5 per group). Significance was measured by one-way ANOVA with Bonferroni post hoc test (E, I, and K). *P < 0.05; **P < 0.01; ***P < 0.001.